Benefits
Vulvovaginal comfort scores in pregnant women
In 78 pregnant women with a diagnosed vaginal yeast infection, all given a 3-day clotrimazole suppository, irritation, discharge and burning scores fell on two capsules a day for 8 weeks. The abstract words this as compared with placebo, but a later review lists separate P values for each group, and placebo also improved by week 8, so a difference between groups is not confirmed.
Daily-life and emotional well-being scores during pregnancy
In the same trial, the abstract reports less concern about symptoms and less disruption of daily activities on the blend at weeks 4 and 8, but a later review lists these P values separately for each group. Fewer recurrences of emotional and social stress than on placebo are also reported, and sexual impact did not differ. All women also used clotrimazole.
Registered main outcome: how often the infection returned
The trial registration names recurrence over 8 weeks as the main outcome, and the paper title and the maker say recurrences fell. The abstracts give no recurrence counts per group, and the full paper could not be read. A pooled analysis of pregnancy trials of various probiotics found no significant effect on clearing vaginal yeast infections.
Vaginal lactobacilli and yeast levels
In swab samples from the same trial, Candida glabrata fell in the lower vagina on the blend but not on placebo, and Candida albicans and C. glabrata kept falling over 8 weeks in the upper vagina. L. crispatus rose over time on the blend and fell on placebo; these are changes within each group, and fewer women were sampled by week 8. These are laboratory counts, not symptoms, and both groups used clotrimazole.
Vaginal and gut bacteria balance during pregnancy
On placebo, the upper vaginal flora shifted over 8 weeks, with fewer Lactobacillus and more Prevotella and Atopobium, and gut Firmicutes fell; on the blend these profiles stayed unchanged. Bacterial profiles are markers rather than felt outcomes, and they come from the same 78-woman trial with clotrimazole co-treatment.
Bowel movement frequency in pregnant women
The abstract reports more bowel movements per week on the blend than on placebo at weeks 4 and 8; the full paper could not be read to confirm how this was tested. This was one of several questionnaire outcomes in the trial, and constipation itself was not a main outcome.
Mechanism of action
Strains selected for adhesion and hydrogen peroxide
According to the trial authors, the six strains were patented for women's health in Taiwan and China because in laboratory tests they stuck to HeLa cells, a human cervical cell line, and made hydrogen peroxide, which inhibits urogenital microbes such as Escherichia coli, Candida albicans and Gardnerella vaginalis. This is lab work, not human evidence.
Vaginal inflammation markers
In swabs from the pregnancy trial, the pro-inflammatory signal TNF-alpha rose on placebo, while the need for the anti-inflammatory signals IL-4 and IL-10 fell over time on the blend, which the authors read as a shorter period of inflammation. These are marker results from one trial with clotrimazole co-treatment.
Gut-vaginal axis, with no strain tracking
The blend is swallowed, and the proposed route is through the gut to the vagina. The lactobacilli that rose in the vagina, L. crispatus and L. jensenii, are not in the blend, and the papers read did not report whether the six product strains themselves reached the vagina.
Clinical trials
Randomized, double-blind, placebo-controlled trial at Universiti Sains Malaysia and Ministry of Health clinics in Kelantan (NCT03940612); two capsules a day of SynForU-HerCare (9.5 log CFU per capsule) or maltodextrin placebo for 8 weeks, and every woman also used a clotrimazole 200 mg vaginal suppository for 3 days; products supplied by Synbio Tech, which is listed as a collaborator, and no author lists a Synbio Tech affiliation; the same trial also appears in two microbiota papers. (Ang et al. 2022, J Appl Microbiol)
78 pregnant adults at 14 to 32 weeks with a confirmed vaginal yeast infection (39 per group).
The registered main outcome was recurrence over 8 weeks; the abstract states recurrences fell but gives no counts per group, and no registry results are posted. The abstract reports lower irritation (P = 0.023) and discharge (P = 0.011) from week 4 and burning by week 8 (P = 0.046) on the blend, worded as compared with placebo. A 2026 review instead lists separate P values for each group (irritation 0.032 vs 0.067 at week 4; at week 8 irritation below 0.0001 vs 0.001 and discharge 0.002 vs 0.005), so placebo also improved and a direct between-group test is not confirmed. Concern about symptoms and daily-activity scores follow the same pattern. More weekly bowel movements were reported on the blend, and sexual impact scores did not differ. Adverse events are not reported in the abstracts or the Microorganisms full text.